Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.46
CHE's Cash to Debt is ranked higher than
76% of the 232 Companies
in the Global Medical Care industry.

( Industry Median: 0.28 vs. CHE: 0.46 )
CHE' s 10-Year Cash to Debt Range
Min: 0   Max: 2.78
Current: 0.46

0
2.78
Equity to Asset 0.48
CHE's Equity to Asset is ranked higher than
73% of the 233 Companies
in the Global Medical Care industry.

( Industry Median: 0.47 vs. CHE: 0.48 )
CHE' s 10-Year Equity to Asset Range
Min: 0.31   Max: 0.61
Current: 0.48

0.31
0.61
Interest Coverage 10.62
CHE's Interest Coverage is ranked higher than
78% of the 156 Companies
in the Global Medical Care industry.

( Industry Median: 6.48 vs. CHE: 10.62 )
CHE' s 10-Year Interest Coverage Range
Min: 1.85   Max: 12
Current: 10.62

1.85
12
F-Score: 6
Z-Score: 4.94
M-Score: -3.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 10.94
CHE's Operating margin (%) is ranked higher than
78% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 9.71 vs. CHE: 10.94 )
CHE' s 10-Year Operating margin (%) Range
Min: -2.6   Max: 11.56
Current: 10.94

-2.6
11.56
Net-margin (%) 6.24
CHE's Net-margin (%) is ranked higher than
77% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 4.97 vs. CHE: 6.24 )
CHE' s 10-Year Net-margin (%) Range
Min: -3.61   Max: 10.72
Current: 6.24

-3.61
10.72
ROE (%) 19.70
CHE's ROE (%) is ranked higher than
96% of the 223 Companies
in the Global Medical Care industry.

( Industry Median: 9.92 vs. CHE: 19.70 )
CHE' s 10-Year ROE (%) Range
Min: -5.85   Max: 23.56
Current: 19.7

-5.85
23.56
ROA (%) 10.39
CHE's ROA (%) is ranked higher than
94% of the 231 Companies
in the Global Medical Care industry.

( Industry Median: 3.98 vs. CHE: 10.39 )
CHE' s 10-Year ROA (%) Range
Min: -3.02   Max: 10.8
Current: 10.39

-3.02
10.8
ROC (Joel Greenblatt) (%) 170.14
CHE's ROC (Joel Greenblatt) (%) is ranked higher than
97% of the 230 Companies
in the Global Medical Care industry.

( Industry Median: 17.97 vs. CHE: 170.14 )
CHE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -14.36   Max: 185.32
Current: 170.14

-14.36
185.32
Revenue Growth (%) 12.20
CHE's Revenue Growth (%) is ranked higher than
86% of the 182 Companies
in the Global Medical Care industry.

( Industry Median: 7.10 vs. CHE: 12.20 )
CHE' s 10-Year Revenue Growth (%) Range
Min: -19.5   Max: 42.9
Current: 12.2

-19.5
42.9
EBITDA Growth (%) 12.00
CHE's EBITDA Growth (%) is ranked higher than
84% of the 164 Companies
in the Global Medical Care industry.

( Industry Median: 7.20 vs. CHE: 12.00 )
CHE' s 10-Year EBITDA Growth (%) Range
Min: -31.3   Max: 52.3
Current: 12

-31.3
52.3
EPS Growth (%) 12.30
CHE's EPS Growth (%) is ranked higher than
81% of the 145 Companies
in the Global Medical Care industry.

( Industry Median: 9.80 vs. CHE: 12.30 )
CHE' s 10-Year EPS Growth (%) Range
Min: -15.4   Max: 56.8
Current: 12.3

-15.4
56.8
» CHE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

CHE Guru Trades in Q1 2013

Jim Simons 16,900 sh (New)
John Keeley 19,440 sh (+4.47%)
Mario Gabelli 777,320 sh (+0.06%)
Joel Greenblatt 89,155 sh (-5.56%)
Chuck Royce 1,422,242 sh (-21.99%)
» More
Q2 2013

CHE Guru Trades in Q2 2013

Paul Tudor Jones 4,900 sh (New)
Steven Cohen 87,652 sh (New)
Joel Greenblatt 149,723 sh (+67.94%)
John Keeley 23,510 sh (+20.94%)
Mario Gabelli 859,903 sh (+10.62%)
Jim Simons Sold Out
Chuck Royce 1,412,670 sh (-0.67%)
» More
Q3 2013

CHE Guru Trades in Q3 2013

Richard Pzena 360,943 sh (New)
Joel Greenblatt 243,527 sh (+62.65%)
John Keeley 27,010 sh (+14.89%)
Mario Gabelli 875,633 sh (+1.83%)
Chuck Royce 1,413,195 sh (+0.04%)
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2013

CHE Guru Trades in Q4 2013

John Hussman 61,000 sh (New)
Joel Greenblatt 274,224 sh (+12.61%)
John Keeley 28,910 sh (+7.03%)
Chuck Royce 1,443,220 sh (+2.12%)
Mario Gabelli 881,698 sh (+0.69%)
Richard Pzena 362,343 sh (+0.39%)
» More
» Details

Insider Trades

Latest Guru Trades with CHE

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Hussman 2013-12-31 New Buy0.33%$66.14 - $79.93 $ 87.2618%61000
Joel Greenblatt 2013-09-30 Add 62.65%0.22%$66.04 - $75.88 $ 87.2623%243527
Joel Greenblatt 2013-06-30 Add 67.94%0.19%$63.9 - $81.79 $ 87.2619%149723
John Keeley 2013-06-30 Add 20.94%0.01%$63.9 - $81.79 $ 87.2619%23510
John Keeley 2012-06-30 Add 45.36%0.01%$54.78 - $64.06 $ 87.2647%17240
Joel Greenblatt 2012-03-31 Add 41.49%0.13%$51.18 - $63.87 $ 87.2660%84545
Ron Baron 2012-03-31 Sold Out 0.12%$51.18 - $63.87 $ 87.2660%0
John Keeley 2012-03-31 Add 44.81%$51.18 - $63.87 $ 87.2660%11860
Joel Greenblatt 2011-12-31 Add 110.65%0.19%$48.24 - $60.68 $ 87.2664%59753
Ron Baron 2011-12-31 Reduce -50.18%0.14%$48.24 - $60.68 $ 87.2664%371627
John Keeley 2011-12-31 New Buy0.01%$48.24 - $60.68 $ 87.2664%8190
Joel Greenblatt 2011-09-30 Add 131.33%0.14%$50.64 - $67.08 $ 87.2649%28366
Joel Greenblatt 2011-06-30 Add 65.9%0.04%$63.94 - $72.02 $ 87.2630%12262
Joel Greenblatt 2011-03-31 New Buy0.15%$61.96 - $66.71 $ 87.2636%7391
Mario Gabelli 2011-03-31 Reduce -25.49%0.12%$61.96 - $66.71 $ 87.2636%715875
Jean-Marie Eveillard 2011-03-31 Sold Out $61.96 - $66.71 $ 87.2636%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Chemed Corporation

Mario Gabelli Comments on Chemed Corp. - Jan 29, 2014

Chemed Corp. (CHE)(0.3%) (CHE - $76.62 - NYSE) , based in Cincinnati, OH, is a holding company that owns the Vitas hospice company and the Roto Rooter plumbing business. Vitas is the nation's largest hospice company, with almost $1 billion in annual sales. The company is currently facing headwinds from government billing changes and a regulatory investigation, but its management is working hard to protect margins and it should begin to move beyond these issues in 2014. Roto Rooter is enjoying steady revenue growth and record profitability as the economy, particularly the housing market, improves. With strong free cash flow and modest capital expenditures, Chemed is returning the vast majority of its cash flow to shareholders via significant share repurchases.

 

From Mario Gabelli (Trades, Portfolio)’s Gabelli Asset Fund fourth quarter 2013 commentary.

Check out Mario Gabelli latest stock trades

Top Ranked Articles about Chemed Corporation

Mario Gabelli Comments on Chemed Corp.
Chemed Corp. (CHE)(0.3%) (CHE - $76.62 - NYSE) , based in Cincinnati, OH, is a holding company that owns the Vitas hospice company and the Roto Rooter plumbing business. Vitas is the nation's largest hospice company, with almost $1 billion in annual sales. The company is currently facing headwinds from government billing changes and a regulatory investigation, but its management is working hard to protect margins and it should begin to move beyond these issues in 2014. Roto Rooter is enjoying steady revenue growth and record profitability as the economy, particularly the housing market, improves. With strong free cash flow and modest capital expenditures, Chemed is returning the vast majority of its cash flow to shareholders via significant share repurchases. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 20.40
CHE's P/E(ttm) is ranked higher than
73% of the 175 Companies
in the Global Medical Care industry.

( Industry Median: 21.80 vs. CHE: 20.40 )
CHE' s 10-Year P/E(ttm) Range
Min: 10.7   Max: 41.64
Current: 20.4

10.7
41.64
P/B 3.60
CHE's P/B is ranked higher than
52% of the 223 Companies
in the Global Medical Care industry.

( Industry Median: 2.28 vs. CHE: 3.60 )
CHE' s 10-Year P/B Range
Min: 1.63   Max: 5.08
Current: 3.6

1.63
5.08
P/S 1.15
CHE's P/S is ranked higher than
62% of the 234 Companies
in the Global Medical Care industry.

( Industry Median: 1.37 vs. CHE: 1.15 )
CHE' s 10-Year P/S Range
Min: 0.67   Max: 2.46
Current: 1.15

0.67
2.46
PFCF 10.15
CHE's PFCF is ranked higher than
85% of the 164 Companies
in the Global Medical Care industry.

( Industry Median: 15.52 vs. CHE: 10.15 )
CHE' s 10-Year PFCF Range
Min: 7.11   Max: 47.43
Current: 10.15

7.11
47.43
EV-to-EBIT 11.77
CHE's EV-to-EBIT is ranked higher than
83% of the 200 Companies
in the Global Medical Care industry.

( Industry Median: 17.77 vs. CHE: 11.77 )
CHE' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 124.3
Current: 11.77

6.9
124.3
PEG 1.91
CHE's PEG is ranked higher than
73% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 1.93 vs. CHE: 1.91 )
CHE' s 10-Year PEG Range
Min: 0.3   Max: 5.71
Current: 1.91

0.3
5.71
Shiller P/E 22.54
CHE's Shiller P/E is ranked higher than
75% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 24.97 vs. CHE: 22.54 )
CHE' s 10-Year Shiller P/E Range
Min: 15.74   Max: 137.8
Current: 22.54

15.74
137.8

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.90
CHE's Dividend Yield is ranked lower than
80% of the 139 Companies
in the Global Medical Care industry.

( Industry Median: 1.72 vs. CHE: 0.90 )
CHE' s 10-Year Dividend Yield Range
Min: 0.35   Max: 1.42
Current: 0.9

0.35
1.42
Dividend Payout 0.26
CHE's Dividend Payout is ranked higher than
79% of the 112 Companies
in the Global Medical Care industry.

( Industry Median: 0.35 vs. CHE: 0.26 )
CHE' s 10-Year Dividend Payout Range
Min: 0.07   Max: 11
Current: 0.26

0.07
11
Dividend growth (3y) 23.60
CHE's Dividend growth (3y) is ranked higher than
92% of the 79 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. CHE: 23.60 )
CHE' s 10-Year Dividend growth (3y) Range
Min: -42.4   Max: 35.7
Current: 23.6

-42.4
35.7
Yield on cost (5-Year) 2.17
CHE's Yield on cost (5-Year) is ranked higher than
55% of the 144 Companies
in the Global Medical Care industry.

( Industry Median: 2.06 vs. CHE: 2.17 )
CHE' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 3.43
Current: 2.17

0.85
3.43
Share Buyback Rate 5.30
CHE's Share Buyback Rate is ranked higher than
96% of the 162 Companies
in the Global Medical Care industry.

( Industry Median: -1.40 vs. CHE: 5.30 )
CHE' s 10-Year Share Buyback Rate Range
Min: 5.3   Max: -10.2
Current: 5.3

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 0.93
CHE's Price/DCF (Projected) is ranked higher than
78% of the 130 Companies
in the Global Medical Care industry.

( Industry Median: 1.22 vs. CHE: 0.93 )
CHE' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 2.33
Current: 0.93

0.59
2.33
Price/Median PS Value 1.10
CHE's Price/Median PS Value is ranked higher than
64% of the 214 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. CHE: 1.10 )
CHE' s 10-Year Price/Median PS Value Range
Min: 0.44   Max: 1.67
Current: 1.1

0.44
1.67
Price/Peter Lynch Fair Value 2.10
CHE's Price/Peter Lynch Fair Value is ranked higher than
60% of the 67 Companies
in the Global Medical Care industry.

( Industry Median: 1.50 vs. CHE: 2.10 )
CHE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.51   Max: 5.42
Current: 2.1

0.51
5.42
Earnings Yield (Greenblatt) 8.50
CHE's Earnings Yield (Greenblatt) is ranked higher than
82% of the 222 Companies
in the Global Medical Care industry.

( Industry Median: 5.30 vs. CHE: 8.50 )
CHE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 14.5
Current: 8.5

0.8
14.5
Forward Rate of Return (Yacktman) 14.38
CHE's Forward Rate of Return (Yacktman) is ranked higher than
82% of the 171 Companies
in the Global Medical Care industry.

( Industry Median: 11.19 vs. CHE: 14.38 )
CHE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -22.1   Max: 60
Current: 14.38

-22.1
60

Business Description

Industry: Health Care Providers » Medical Care
Compare:FMS, DVA, FSNUY, BDUUF, SKHCY » details
Traded in other countries:CXM.Germany
Chemed Corporation was incorporated in Delaware in 1970 as a subsidiary of W.R. Grace & Co. The Company, through its subsidiaries, operates in the healthcare, and repair and maintenance fields in the United States. Its business is segmented into two - Vitas segment and Roto-Rooter segment. Vitas Healthcare Corporation provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. The Roto-Rooter provides plumbing and drain cleaning services to both residential and commercial customers. Roto-Rooter has manufacturing and distribution center facilities in West Des Moines, Iowa and has 105 leased and owned office and service facilities in 30 states. Vitas operate 51 programs from 146 leased facilities and 36 inpatient units in 18 states and the District of Columbia.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide